Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elite Pharmaceuticals Inc. (ELTP : OTC)

• Company Description    Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $0.52 Daily Weekly Monthly 20 Day Moving Average: 2,422,734 shares Shares Outstanding: 1,070.86 (millions) Market Capitalization: $555.99 (millions) Beta: 0.25 52 Week High: $0.82 52 Week Low: $0.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.48% -27.31% 12 Week 23.33% 3.73% Year To Date -4.05% -10.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 165 LUDLOW AVENUE - NORTHVALE,NJ 07647 USA ph: 201-750-2646 fax: 201-750-2755 dianne@elitepharma.com http://www.elitepharma.com

• General Corporate Information    Officers Nasrat Hakim - Chief Executive Officer Carter Ward - Chief Financial Officer Barry Dash - Director Jeffrey Whitnell - Director Davis Caskey - Director Peer Information Elite Pharmaceuticals Inc. (GSAC) Elite Pharmaceuticals Inc. (CASI) Elite Pharmaceuticals Inc. (ALCD.) Elite Pharmaceuticals Inc. (OMNN) Elite Pharmaceuticals Inc. (CGPI.) Elite Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 28659T200 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 1,070.86 Most Recent Split Date: (:1) Beta: 0.25 Market Capitalization: $555.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.36 Price/Cash Flow: 30.27 Price / Sales: 6.62 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 200.00% Sales Growth vs. Year Ago Period: 78.26% vs. Previous Quarter: 122.75% ROE 06/30/25 - - 03/31/25 - 3.96 12/31/24 - -6.92 ROA 06/30/25 - - 03/31/25 - 2.13 12/31/24 - -3.94 Current Ratio 06/30/25 - - 03/31/25 - 4.88 12/31/24 - 3.27 Quick Ratio 06/30/25 - - 03/31/25 - 3.50 12/31/24 - 1.90 Operating Margin 06/30/25 - - 03/31/25 - 2.30 12/31/24 - -4.93 Net Margin 06/30/25 - - 03/31/25 - -5.13 12/31/24 - -25.70 Pre-Tax Margin 06/30/25 - - 03/31/25 - -0.06 12/31/24 - -24.76 Book Value 06/30/25 - - 03/31/25 - 0.05 12/31/24 - 0.03 Inventory Turnover 06/30/25 - - 03/31/25 - 2.73 12/31/24 - 2.56 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.08 12/31/24 - 0.12 Debt-to-Capital 06/30/25 - - 03/31/25 - 7.41 12/31/24 - 10.73

Powered by Zacks Investment Research ©